A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
Clinical trial NCT06735391 · RECRUITING
Trial details
- NCT number
- NCT06735391
- Sponsor
- Shanghai JMT-Bio Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-23
- Primary completion
- 2026-09-30
- Enrollment
- 516
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.